Showing results (21-30 of 62) with videos related to
Sort By:
Pageof 7
International Journal of Colorectal Disease|May 8, 2008
HLA-A2 expression, stage, and survival in colorectal cancerPhilipp Kiewe, Veit Mansmann, Carmen Scheibenbogen, et al.Leukemia & Lymphoma|May 21, 2009
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomabDirk Nagorsen, Ralf Bargou, Dominik Ruttinger, et al.Journal for Immunotherapy of Cancer|May 13, 2025
Regional distribution of HLA frequencies in the USA: implications for TCR-based therapiesChristian Roy, Tomasz Sewastianik, Ileana Saenz, et al.International Journal of Cancer|April 4, 2003
Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patientsDirk Nagorsen, Carmen Scheibenbogen, Gerhard Schaller, et al.Cancer Immunology, Immunotherapy : CII|May 11, 2004
Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210MDirk Nagorsen, Catherine Servis, Nicole Lévy, et al.Blood|August 30, 2002
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemiaCarmen Scheibenbogen, Anne Letsch, Eckhard Thiel, et al.Experimental Hematology|March 18, 2006
Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytesJong-Baeck Lim, Maurizio Provenzano, Oh Hun Kwon, et al.Journal of Translational Medicine|July 3, 2008
Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populationsSebastian Ochsenreither, Alberto Fusi, Antonia Busse, et al.Cells, Tissues, Organs|September 25, 2004
A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunizationMonica C Panelli, Brian Martin, Dirk Nagorsen, et al.International Journal of Cancer|January 13, 2005
Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patientsAnne Letsch, Ulrich Keilholz, Michael Fluck, et al.Pageof 7